Literature DB >> 7504552

Non-invasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice.

E W Alton1, P G Middleton, N J Caplen, S N Smith, D M Steel, F M Munkonge, P K Jeffery, D M Geddes, S L Hart, R Williamson.   

Abstract

We report gene transfer to the Edinburgh insertional mutant mouse (cf/cf), delivering CFTR cDNA-liposome complexes into the airways by nebulization. We show full restoration of cAMP related chloride responses in some animals and demonstrate, in the same tissues, human CFTR cDNA expression. Overall, a range of correction was seen with restoration of about 50% of the deficit between wild type mice and untreated cf/cf controls. We report modest correction in the intestinal tract following direct instillation and provide initial encouraging safety data for both the respiratory and intestinal tract following the liposome mediated gene delivery. The non-viral nature and potentially lower immunogenicity of DNA-liposomes suggest that this may offer a therapeutic alternative to adenoviral therapies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7504552     DOI: 10.1038/ng1093-135

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  58 in total

Review 1.  The role of CpG in DNA vaccines.

Authors:  M J McCluskie; R D Weeratna; H L Davis
Journal:  Springer Semin Immunopathol       Date:  2000

Review 2.  Aerosol gene therapy.

Authors:  Ajay Gautam; J Clifford Waldrep; Charles L Densmore
Journal:  Mol Biotechnol       Date:  2003-01       Impact factor: 2.695

3.  Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration.

Authors:  C L Halbert; T A Standaert; M L Aitken; I E Alexander; D W Russell; A D Miller
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 4.  A realistic chance for gene therapy in the near future.

Authors:  Stefan Worgall
Journal:  Pediatr Nephrol       Date:  2004-11-10       Impact factor: 3.714

5.  Complementation of null CF mice with a human CFTR YAC transgene.

Authors:  A L Manson; A E Trezise; L J MacVinish; K D Kasschau; N Birchall; V Episkopou; G Vassaux; M J Evans; W H Colledge; A W Cuthbert; C Huxley
Journal:  EMBO J       Date:  1997-07-16       Impact factor: 11.598

6.  An international randomized multicenter comparison of nasal potential difference techniques.

Authors:  George M Solomon; Michael W Konstan; Michael Wilschanski; Joanne Billings; Isabelle Sermet-Gaudelus; Frank Accurso; François Vermeulen; Elina Levin; Heather Hathorne; Ginger Reeves; Gina Sabbatini; Aubrey Hill; Nicole Mayer-Hamblett; Melissa Ashlock; John Paul Clancy; Steven M Rowe
Journal:  Chest       Date:  2010-05-14       Impact factor: 9.410

7.  Effects of moisture content on the storage stability of dried lipoplex formulations.

Authors:  Jinxiang Yu; Thomas J Anchordoquy
Journal:  J Pharm Sci       Date:  2009-09       Impact factor: 3.534

Review 8.  Cystic fibrosis gene update.

Authors:  A Cuthbert
Journal:  J R Soc Med       Date:  1994       Impact factor: 5.344

9.  Targeted gene transfer into hepatoma cells with lipopolyamine-condensed DNA particles presenting galactose ligands: a stage toward artificial viruses.

Authors:  J S Remy; A Kichler; V Mordvinov; F Schuber; J P Behr
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

Review 10.  Barriers to inhaled gene therapy of obstructive lung diseases: A review.

Authors:  Namho Kim; Gregg A Duncan; Justin Hanes; Jung Soo Suk
Journal:  J Control Release       Date:  2016-05-16       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.